Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Votrient (pazopanib) will now be available for access by patients of advanced renal cell carcinoma (RCC) living in England and Wales on the National Health Service (NHS).
Subscribe to our email newsletter
Votrient is a targeted oral treatment, which is an effective first-line treatment for advanced renal cell carcinoma (as acknowledged by NICE) since it slows down progression of the disease and simultaneously maintains a patient’s quality of life compared with placebo.
It is tyrosine kinase inhibitor (TKI) which inhibits angiogenesis, thereby slowing tumour growth and cancer metastasis.
The National Institute for Health and Clinical Excellence (NICE) has also issued positive final guidance (Technology Appraisal Guidance or TAG) for Votrient.
To help patients who are in advanced stages of RCC, GlaxoSmithKline (GSK) has proposed an innovative and flexible pricing scheme to NICE where it has expressed its willingness to extend a potential partial rebate, conditional upon the outcome of the COMPARZ trial (the current standard-of-care).
GSK is confident that the appropriate evidence will be generated failing which GSK will pay the NHS a partial rebate.
GSK UK general manager Simon Jose said advanced kidney cancer is a devastating disease and they are pleased that through this pricing scheme they are able to offer patients rapid access to Votrient whilst delivering value for money to the NHS.
"GSK’s pricing scheme was aimed at providing patients rapid access to Votrient whilst delivering value for money to the NHS," Jose said.